- Home
- NERV vs CABR Comparison
NERV vs CABR Comparison
Compare NERV & CABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- CABR
- Stock Information
- Founded
- NERV 2007
- CABR 2020
- Country
- NERV United States
- CABR United States
- Employees
- NERV N/A
- CABR N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- CABR Package Goods/Cosmetics
- Sector
- NERV Health Care
- CABR Consumer Discretionary
- Exchange
- NERV Nasdaq
- CABR Nasdaq
- Market Cap
- NERV 14.6M
- CABR 14.1M
- IPO Year
- NERV 2014
- CABR N/A
- Fundamental
- Price
- NERV $3.78
- CABR $1.00
- Analyst Decision
- NERV Hold
- CABR
- Analyst Count
- NERV 1
- CABR 0
- Target Price
- NERV $4.00
- CABR N/A
- AVG Volume (30 Days)
- NERV 101.0K
- CABR 597.4K
- Earning Date
- NERV 11-05-2025
- CABR 01-01-0001
- Dividend Yield
- NERV N/A
- CABR N/A
- EPS Growth
- NERV N/A
- CABR N/A
- EPS
- NERV N/A
- CABR N/A
- Revenue
- NERV N/A
- CABR $4,493.00
- Revenue This Year
- NERV N/A
- CABR N/A
- Revenue Next Year
- NERV N/A
- CABR N/A
- P/E Ratio
- NERV N/A
- CABR N/A
- Revenue Growth
- NERV N/A
- CABR N/A
- 52 Week Low
- NERV $1.15
- CABR $0.06
- 52 Week High
- NERV $12.46
- CABR $6.00
- Technical
- Relative Strength Index (RSI)
- NERV 49.13
- CABR N/A
- Support Level
- NERV $3.76
- CABR N/A
- Resistance Level
- NERV $4.42
- CABR N/A
- Average True Range (ATR)
- NERV 0.32
- CABR 0.00
- MACD
- NERV -0.09
- CABR 0.00
- Stochastic Oscillator
- NERV 25.93
- CABR 0.00
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.